A phase II trial of interleukin-2 in myelodysplastic syndromes

British Journal of Haematology

Volumn 101, Issue 1, 1998, Pages 205-207

  Nand, Sucha ^a   Stock, Wendy ^a   Stiff, Patrick ^a   Sosman, Jeffrey ^a   Martone, Brenda ^a   Radvany, Ruta ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Interleukin 2; Myelodysplastic syndromes; Natural killer cells; Preleukaemia

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; LYMPHOCYTE SURFACE MARKER; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031970068     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00672.x     Document Type: Article

References (12)

1. Caligiuri, M.A. (1993) Low-dose recombinant interleukln-2 therapy: rationale and potential clinical applications. Seminars in Oncology, 20, (Suppl. 6), 3-10.
2. Dutcher, J.P. & Wiernik, H. (1993) The role of recombinant interleukin-2 in therapy for hematologic malignancies. Seminars in Oncology, 20, (Suppl. 6), 33-41.
3. Foa, R. (1943) Does interleukin-2 have a role in the management of acute leukemia? Journal of Clinical Oncology, 11, 1817-1825.
4. Ganser, A., Heil, G., Kolbe, K., Maschmeyer, G., Fischer, J.T., Bergmann, L., Mitrou, P.S., Heit, W., Heimpel, H., Huber, C. & Hoelzer, D. (1996) Aggressive chemotherapy combined with G-CSF and maintenance therapy with IL-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia: initial results, Annals of Hematology, 66, 123-125.
5. Hamblin, T. (1992) Immunologic abnormalities in myelodysplastic syndromes. Hematology/Oncology Clinics of North America, 6, 571-586.
6. Hawkins, M.H. (1993) Interleukin-2 antitumor and effector cell responses. Seminars in Oncology, 20, (Suppl. 6), 52-58.
7. Lim, S.H., Newland, A.C., Kelsey, S., Bell, A., Offerman, E., Rist, C., Gozzard, D., Bareford, D., Smith, M.P. & Goldstone, A.H. (1992) Continuous infusion of high-dose recombinant interleukin-2 for acute myeloid leukemia: a phase II study. Cancer Immunology and Immunotherapy, 34, 337-342.
8. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M., Sainty, D., Marit, G., Stoppa, A.M., Reiffers, J., Gratecos, N., Bertau-Perez, P., Mannoni, P., Mawas, C., Hercend, T., Sebahoun, G. & Carcassonne, Y. (1991) High-dose recombinant interleukin-2 in acute myeloid leukemia in relapse. Blood, 78, 2182-2187.
9. Meropol, N.J., Porter, M., Blumenson, L.E., Lindemann, M.J., Perez, R.P., Vaickus, L., Loewen, G.M., Creaven, P.J., Wilkes, K.A., Geidlen, M.A. & Caligiuri, M.A. (1996) Daily subcutaneous injection of low dose interleukin-2 expands natural killer cells in vivo without significant toxicity. Cancer Clinical Research, 2, 669-677.
10. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aubersold, P.M., Linehan, W.M., Seipp, C.A. & White, D.E. (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 Cancer patients, Annals of Surgery, 210, 474-485.
11. Schumacher, H.R. & Nand, S. (1995) Myelodysplastic Syndromes: an Approach to Diagnosis and Treatment, pp. 150-178. Igaku Shoin, New York.
12. Tone, C.L., Barnett, M.J. & Klingemann, H.G. (1993) Response of therapy related myelodysplasia to low-dose interleukin-2, Leukemia, 7, 463-465.